Depressive Disorder News and Research

RSS

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Reviva Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the discovery and development of new, safer and highly effective therapies for chronic indications, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration for its lead, new investigational antipsychotic drug, RP5063.

5 Nov 2013

FDA approves Prior Approval Supplement for EMBEDA Extended Release Capsules CII

Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved a Prior Approval Supplement for EMBEDA (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII.

4 Nov 2013

Alkermes reports 38% of year-over-year revenue growth from key products

Alkermes plc today reported financial results for the quarter ended Sept. 30, 2013. This is the second quarter of the nine-month period ending Dec. 31, 2013, as the company transitions to reporting on a calendar year basis.

31 Oct 2013

e-Therapeutics begins ETS6103 phase IIb trial for major depressive disorder

e-Therapeutics plc announces that it has started a randomised double-blind controlled phase IIb trial of ETS6103 in major depressive disorder.

31 Oct 2013

Serotonin 2C receptors induce fast-acting antidepressant effects in mice

More than 1 in 10 Americans take antidepressants, but these medications can take weeks-and for some patients, months-before they begin to alleviate symptoms. Now, scientists from the University of Chicago have discovered that selectively blocking a serotonin receptor subtype induces fast-acting antidepressant effects in mice, indicating a potential new class of therapeutics for depression. The work was published Oct. 29 in Molecular Psychiatry.

29 Oct 2013

Multifactorial approach needed for early bipolar detection

At-risk states for bipolar disorder require a multifaceted approach to be identified and appropriately treated, according to preliminary results from the Dresden High-Risk Project.

24 Oct 2013

Researchers find relationship between solar intensity and ADHD prevalence

Attention-deficit/hyperactivity disorder, or ADHD, is the most common childhood psychiatric disorder. Scientists do not know what causes it, but genetics play a clear role. Other risk factors have also been identified, including premature birth, low birth weight, a mother's use of alcohol or tobacco during pregnancy, and environmental exposures to toxins like lead.

23 Oct 2013

Obesity may aggravate bipolar neuropathology

Being overweight may result in increased white matter loss in key brain regions in patients with bipolar disorder, research suggests.

18 Oct 2013

Bipolar risk markers identified in depressed ADHD children

Researchers have identified risk markers for bipolar I disorder conversion in children with attention deficit hyperactivity disorder and major depressive disorder.

15 Oct 2013

Elsevier journals currently offers 3D visualization services to authors and readers

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and Kitware, a worldwide leader in developing advanced visualization technologies, today announced that Elsevier journals offer the opportunity to upload 3D datasets when submitting a paper for publication. This way, once published, readers can interactively explore 3D datasets next to the online article on ScienceDirect.

15 Oct 2013

DSM-IV insufficient for bipolar disorder diagnosis

Research findings support concerns that the text revision of the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders is too restrictive for diagnosing bipolar disorder.

11 Oct 2013

Alkermes' ALKS 5461 drug gets FDA Fast Track status for major depressive disorder

Alkermes plc today announced that the U.S. Food and Drug Administration has granted Fast Track status for ALKS 5461 for the adjunctive treatment of major depressive disorder in patients with an inadequate response to standard therapies.

10 Oct 2013

Alkermes announces plans to advance ALKS 5461 phase 3 program for major depressive disorder

Alkermes plc today announced that it has successfully completed its End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA), and the company plans to advance ALKS 5461 into phase 3 development in early 2014.

9 Oct 2013

Bipolar disorder ‘distinct’ from borderline personality disorder

Researchers say that there are clear clinical differences between depressed patients with bipolar II disorder and those with borderline personality disorder, which supports the two being treated as distinct conditions.

8 Oct 2013

Brain & Behavior Research Foundation to hold research symposium on mental health

The Brain & Behavior Research Foundation, an organization dedicated to improving the lives of those with mental illness through the transformative power of neuroscience and psychiatric research, will hold its 25th Annual Mental Health Research Symposium on Friday, October 25th from 9:00 am to 4:30 p.m. at the Kaufman Music Center, located at 129 W. 67th St. in New York City.

8 Oct 2013

PMDD may shed light on complex interactions between sex hormones and mood

Improved understanding of the role of female sex hormones on the drivers and symptoms of premenstrual dysphoric disorder (PMDD) may shed light on the complex interactions between sex hormones and mood, potentially helping to explain the increased prevalence of mood disorders in women.

8 Oct 2013